Study of Baclofen Treatment for Alcohol Use Disorder with and without Anxiety Symptoms Evaluating Effects on Abstinence and Anxiety Over Six Weeks

What this Trial Is About

This research aims to evaluate the effectiveness of baclofen for treating alcohol use disorder AUD in adults, including those with or without anxiety symptoms. It focuses on whether patients with higher anxiety levels experience more days of abstinence and other differences such as drinking behavior, response to treatment, anxiety reduction, craving, motives, and side effects. Participants are already using baclofen as part of their usual care for AUD. The study involves a single group where baclofen is given as standard care, with dosage adjusted by the treating doctor based on tolerance. The intervention itself consists of completing various questionnaires throughout a 6-week period. These questionnaires assess alcohol use, anxiety, craving, autonomic symptoms, drinking motives, and side effects. Participants will answer these questionnaires weekly or bi-weekly over the 6 weeks, starting from hospitalization or baclofen initiation. Researchers will measure the number of days participants remain abstinent each week and evaluate changes in drinking behavior, anxiety scores, autonomic responses, craving levels, treatment response, and side effects. This study spans a total of 6 weeks with no additional treatment interventions beyond standard care baclofen.

Baclofen for Anxiety and Alcohol Use Disorder (AUD): an Open Label Study